An FDA advisory panel narrowly recommended expanding access to compounded, unapproved peptides including BPC-157 and KPV, a decision that would loosen restrictions for patients and compound pharmacies if adopted by the agency. The vote was framed by proponents as broader access and by critics as continuing evidence and safety concerns. The panel’s recommendation came ahead of additional votes that would consider other peptides, with the FDA ultimately deciding whether to lift current limitations. Although advisory votes are non-binding, the outcome represents a notable moment in a controversial regulatory pathway for compounded drugs using bulk substances. The debate centers on whether compounding should expand beyond existing controls when clinical evidence for safety and effectiveness is limited. It also raises questions about manufacturing standards and adverse event reporting compared with approved branded or generic products. The FDA process continued to underscore the tension between patient demand for these niche wellness-related compounds and the agency’s evidence-based standards for market authorization.